Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy

Li, Enliang; Huang, Xing; Zhang, Gang; Liang, Tingbo

doi:10.1186/s13046-021-02055-w

Journal of Experimental & Clinical Cancer Research

Table 1 Prognostic profile of RTK family subtypes in pancreatic cancer

From: Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy

Type	RTK	CD8 + T-cells-enriched			CD8 + T-cells-decreased
Type	RTK	Prognosis	P-value	HR	Prognosis	P-value	HR
I	EGFR	Unfavor	0.00046	5.94	Unfavor	0.061	1.67
	ERBB2	Unfavor	0.0015	5.57	Unfavor	0.077	1.59
	ERBB3	Unfavor	0.0097	2.54	Unfavor	0.054	1.71
	ERBB4	Unfavor	0.054	1.96	Favor	0.13	0.66
II	INSR	Favor	0.088	0.48	Unfavor	0.31	1.32
	IGF1R	Unfavor	0.11	1.74	Favor	0.12	0.67
	INSRR	Unfavor	0.24	1.65	Favor	0.03	0.49
III	PDGFRA	Unfavor	0.043	2.25	Unfavor	0.093	1.75
	PDGFRB	Unfavor	0.018	2.29	Unfavor	0.33	1.3
	CSF1R	Unfavor	0.019	2.31	Favor	0.17	0.69
	KIT	Unfavor	0.18	1.77	Favor	0.21	0.7
	FLT3	Unfavor	0.24	1.58	Unfavor	0.34	1.29
IV	FLT1	Favor	0.04	0.47	Unfavor	0.041	1.72
	KDR	Favor	0.12	0.53	Favor	0.22	0.71
	FLT4	Favor	0.048	0.5	Favor	0.31	0.76
V	FGFR1	Favor	0.0031	0.35	Favor	0.44	0.81
	FGFR2	Unfavor	0.097	2.22	Favor	0.02	0.48
	FGFR3	Favor	0.08	0.44	Unfavor	0.2	1.44
	FGFR4	Favor	0.32	0.67	Favor	0.14	0.65
VI	PTK7	Unfavor	0.0045	2.66	Unfavor	0.15	1.47
VII	NTRK1	Unfavor	0.24	1.59	Favor	0.31	0.71
	NTRK2	Unfavor	0.49	1.29	Favor	0.15	0.65
	NTRK3	Unfavor	0.17	1.78	Favor	0.48	0.82
VIII	ROR1	Unfavor	0.0054	2.64	Unfavor	0.12	1.54
VIII	ROR2	Unfavor	0.11	1.76	Favor	0.01	0.49
IX	MUSK	Unfavor	0.026	3.11	Unfavor	0.34	1.28
X	MET	Unfavor	0.0014	5.64	Unfavor	1.4e-05	3.01
X	MST1R	Unfavor	0.0093	2.48	Unfavor	0.084	1.74
XI	TYRO3	Unfavor	0.17	1.65	Favor	0.14	0.67
	AXL	Unfavor	0.0044	4.27	Unfavor	0.064	1.63
	MERTK	Unfavor	0.06	2.15	Favor	0.08	0.63
XII	TIE1	Favor	0.089	0.55	Favor	0.086	0.64
XII	TEK	Unfavor	0.37	1.47	Favor	0.18	0.7
XIII	EPHA1	Unfavor	0.24	1.54	Favor	0.25	0.74
	EPHA2	Unfavor	0.021	2.24	Unfavor	0.073	1.75
	EPHA3	Unfavor	0.066	2.4	Unfavor	0.47	1.22
	EPHA4	Unfavor	0.039	2.88	Unfavor	0.17	1.44
	EPHA5	Favor	0.28	0.64	Favor	0.058	0.54
	EPHA6	Favor	0.1	0.46	Favor	0.42	0.79
	EPHA7	Unfavor	0.23	1.52	Favor	0.028	0.52
	EPHA8	Unfavor	0.063	1.99	Favor	0.26	0.71
	EPHA10	Favor	0.021	0.38	Favor	0.033	0.56
	EPHB1	Favor	0.16	0.61	Unfavor	0.12	1.54
	EPHB2	Unfavor	0.0012	3.21	Unfavor	0.27	1.35
	EPHB3	Unfavor	0.27	1.5	Unfavor	0.28	1.4
	EPHB4	Unfavor	0.01	3.17	Unfavor	0.27	1.35
	EPHB6	Unfavor	0.012	2.55	Unfavor	0.039	1.87
XIV	RET	Favor	0.072	0.52	Favor	0.11	0.62
XV	RYK	Unfavor	0.012	3.06	Unfavor	0.003	2.15
XVI	DDR1	Favor	0.23	1.53	Unfavor	0.46	1.25
XVI	DDR2	Unfavor	0.0016	3.41	Favor	0.32	0.77
XVII	ROS1	Unfavor	0.062	1.93	Favor	0.18	0.7
XVIII	AATK	Favor	0.0038	0.36	Favor	0.055	0.58
	LMTK2	Unfavor	0.23	1.79	Favor	0.0067	0.47
	LMTK3	Favor	0.21	0.6	Favor	0.093	0.64
XIX	LTK	Unfavor	0.49	1.28	Favor	0.0016	0.43
XIX	ALK	Favor	0.0051	0.3	Favor	0.012	0.41
XX	STYK1	Unfavor	0.016	3.41	Unfavor	0.065	1.63

Back to article page

ISSN: 1756-9966

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com